1 rly endosome indicating translocation of the chimeric toxin.

2 n be manipulated by molecular engineering of chimeric toxins.

3 e conclude that biochemical targeting of the chimeric toxin and physical targeting of ionizing radiat

4 l or systemic toxicity was observed with the chimeric toxin and radiation.

5 ant cells exhibited similar responses to the chimeric toxins and interleukins when compared with that

6 enotype, we constructed enzymatically active chimeric toxins and mutant toxins that contained single

7 old mice given nasal tetanus toxoid plus the chimeric toxin as adjuvant were protected from lethal ch

8 ype s1/m1 toxin was added to HeLa cells, the chimeric toxin completely inhibited the activity of the

9 te in blastocyst activation, the toxicity of chimeric toxins composed of HB-EGF or TGF-(&agr;) couple

10                            Analysis of these chimeric toxins confirmed that toxin-induced signal tran

11 ct rabbit portal vein smooth muscle with the chimeric toxin DC3B (10(-6) M, 48 h; ; ) ADP-ribosylated

12                   CD4-PE40 and 3B3(Fv)-PE38, chimeric toxins designed to target the HIV envelope (Env

13                                          The chimeric toxins had attenuated affinity for binding to h

14      Of interest, a corresponding hIL4-based chimeric toxin, hIL4-PE38QQR, is poorly active or not ac

15                                          The chimeric toxins, however, were much less potent than wt

16 ible to hIL13-PE38QQR, and the action of the chimeric toxin is not blocked by hIL4 on all these cells

17                             As a first step, chimeric toxins of ProTx II and PaTx I were synthesized

18 udy the proteolytic processing of PE-derived chimeric toxins, TGFalpha-PE38 (transforming growth fact

19 ndent manner and reduced the binding of this chimeric toxin to HEp-2 cells.

20 branes and signal transduction, CT and LTIIb chimeric toxins were prepared.